<p>uniQure（納斯達克股票代碼：QURE - 獲取免費報告）在週四的交易中下跌了 4.2%。該公司的股價最低曾達到 12.99 美元，最後交易價為 13.08 美元。在午盤交易中，共成交 453,645 股，較平均交易量 1,015,442 股下降了 55%。該股票此前收盤價為 13.65 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>多位股票分析師最近對 QURE 股票發佈了報告。StockNews.com 在 3 月 11 日的研究報告中將 uniQure 的評級上調至 “賣出”。Guggenheim 在 12 月 11 日的研究報告中重申了對 uniQure 股票的 “買入” 評級。加拿大皇家銀行在 1 月 21 日的研究報告中重申了 “跑贏大盤” 評級，並對 uniQure 股票設定了 24.00 美元的目標價。Raymond James 在 12 月 10 日的研究報告中將 uniQure 的評級從 “跑贏大盤” 上調至 “強力買入”，並將其目標價從 20.00 美元提高至 52.00 美元。最後，高盛集團在 12 月 12 日的研究報告中將 uniQure 的目標價從 9.00 美元提高至 20.00 美元，並給予該股票 “中性” 評級。一位研究分析師對該股票給予了賣出評級，三位給予了持有評級，六位給予了買入評級，還有一位給予了強力買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 38.89 美元。</p>
<p><strong>獲取我們對 uniQure 的最新股票分析</strong></p>
<h2>uniQure 價格表現</h2>
<p>該公司的債務與股本比率為 0.92，速動比率為 6.51，流動比率為 6.51。該公司的市值為 6.732 億美元，市盈率為-2.50，貝塔值為 0.36。該公司的 50 日移動平均線為 13.82 美元，200 日移動平均線為 10.69 美元。</p>
<h2>uniQure 的內部買賣</h2>
<p>在其他消息中，首席執行官 Matthew C. Kapusta 在 3 月 4 日的交易中出售了 28,341 股公司的股票。該股票以平均價格 10.29 美元出售，總交易額為 291,628.89 美元。出售後，首席執行官現在直接持有 651,454 股公司的股票，價值為 6,703,461.66 美元。這代表其持股減少了 4.17%。該交易在向證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席財務官 Christian Klemt 在 2 月 27 日的交易中出售了 2,916 股公司的股票。該股票以平均價格 11.32 美元出售，總交易額為 33,009.12 美元。交易完成後，首席財務官現在直接持有 155,168 股公司的股票，價值約為 1,756,501.76 美元。此交易代表其持股減少了 1.84%。該交易的披露信息可在此找到。在過去三個月中，內部人士共出售了 90,830 股公司股票，價值為 961,401 美元。當前 4.74% 的股票由公司內部人士持有。</p>
<h2>對 uniQure 的對沖基金觀點</h2>
<p>機構投資者最近買入和賣出了該公司的股票。Avoro Capital Advisors LLC 在第四季度購買了 uniQure 的新頭寸，價值為 38,410,000 美元。Franklin Resources Inc.在第四季度將其在 uniQure 的持股增加了 33.1%。Franklin Resources Inc.現在持有 1,987,688 股生物技術公司的股票，價值為 35,103,000 美元，此前在上個季度又購買了 494,726 股。Point72 Asset Management L.P.在第四季度將其在 uniQure 的持股增加了 81.3%。Point72 Asset Management L.P.現在持有 1,771,352 股生物技術公司的股票，價值為 31,282,000 美元，此前在該期間又購買了 794,459 股。Integral Health Asset Management LLC 在第四季度將其在 uniQure 的持股增加了 175.0%。Integral Health Asset Management LLC 現在持有 1,100,000 股生物技術公司的股票，價值為 19,426,000 美元，此前在上個季度又購買了 700,000 股。最後，RTW Investments LP 在第四季度將其在 uniQure 的持股增加了 8,936.3%。RTW Investments LP 現在持有 903,625 股生物技術公司的股票，價值為 15,958,000 美元，此前在該期間又購買了 893,625 股。機構投資者持有該公司 78.83% 的股票。</p>
<h2>uniQure 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>uniQure N.V.為患有罕見和其他嚴重疾病的患者開發治療方案。它提供的 HEMGENIX 已完成針對 B 型血友病的 III 期 HOPE-B 關鍵試驗。該公司還開發了 AMT-130，這是一種正在進行 I/II 期臨牀研究的基因治療，用於治療亨廷頓舞蹈症。</p>
<h2>推薦閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 uniQure</li>
<li>如何投資 FAANG 股票</li>
<li>便士股票激增，SurgePays 上漲 70%：買入的一個理由，賣出的五個理由</li>
<li>什麼是歐元 STOXX 50 指數？</li>
<li>三大飲料股票帶來豐厚利潤</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>CarMax 和 Carvana：引領二手車市場</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 uniQure 嗎？</h2>
<p>在你考慮 uniQure 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 uniQure 並不在名單上。</p>
<p>雖然 uniQure 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

QURE

<p>uniQure（納斯達克股票代碼：QURE）股價下跌 4.2%，至 13.08 美元，交易量較平均水平下降 55%。分析師的評級意見不一，其中一位為賣出，三位為持有，六位為買入，一位為強烈買入。平均評級為 “適度買入”，目標價為 38.89 美元。最近的內部交易包括首席執行官 Matthew C. Kapusta 出售 28,341 股。機構投資者持有該股票的 78.83%，並在上個季度進行了大量購買。uniQure 專注於罕見疾病的治療，包括 B 型血友病和亨廷頓舞蹈症</p>

<p>Shares of uniQure (NASDAQ:QURE - Get Free Report) traded down 4.2% during trading on Thursday . The company traded as low as $12.99 and last traded at $13.08. 453,645 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 1,015,442 shares. The stock had previously closed at $13.65.</p>
<div class="lb-trans"><p>uniQure（納斯達克股票代碼：QURE - 獲取免費報告）在週四的交易中下跌了 4.2%。該公司的股價最低曾達到 12.99 美元，最後交易價為 13.08 美元。在午盤交易中，共成交 453,645 股，較平均交易量 1,015,442 股下降了 55%。該股票此前收盤價為 13.65 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of equities analysts have recently issued reports on QURE shares. StockNews.com upgraded uniQure to a &#34;sell&#34; rating in a research note on Tuesday, March 11th. Guggenheim reaffirmed a &#34;buy&#34; rating on shares of uniQure in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Raymond James upgraded shares of uniQure from an &#34;outperform&#34; rating to a &#34;strong-buy&#34; rating and boosted their target price for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. Finally, The Goldman Sachs Group increased their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $38.89.</p>
<div class="lb-trans"><p>多位股票分析師最近對 QURE 股票發佈了報告。StockNews.com 在 3 月 11 日的研究報告中將 uniQure 的評級上調至 “賣出”。Guggenheim 在 12 月 11 日的研究報告中重申了對 uniQure 股票的 “買入” 評級。加拿大皇家銀行在 1 月 21 日的研究報告中重申了 “跑贏大盤” 評級，並對 uniQure 股票設定了 24.00 美元的目標價。Raymond James 在 12 月 10 日的研究報告中將 uniQure 的評級從 “跑贏大盤” 上調至 “強力買入”，並將其目標價從 20.00 美元提高至 52.00 美元。最後，高盛集團在 12 月 12 日的研究報告中將 uniQure 的目標價從 9.00 美元提高至 20.00 美元，並給予該股票 “中性” 評級。一位研究分析師對該股票給予了賣出評級，三位給予了持有評級，六位給予了買入評級，還有一位給予了強力買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 38.89 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on uniQure</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 uniQure 的最新股票分析</strong></p>
</div><h2>uniQure Price Performance</h2>
<div class="lb-trans"><h2>uniQure 價格表現</h2>
</div><p>The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market cap of $673.20 million, a P/E ratio of -2.50 and a beta of 0.36. The firm's fifty day moving average is $13.82 and its two-hundred day moving average is $10.69.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 0.92，速動比率為 6.51，流動比率為 6.51。該公司的市值為 6.732 億美元，市盈率為-2.50，貝塔值為 0.36。該公司的 50 日移動平均線為 13.82 美元，200 日移動平均線為 10.69 美元。</p>
</div><h2>Insider Buying and Selling at uniQure</h2>
<div class="lb-trans"><h2>uniQure 的內部買賣</h2>
</div><p>In other news, CEO Matthew C. Kapusta sold 28,341 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at $6,703,461.66. This represents a 4.17 % decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company's stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 in the last three months. 4.74% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官 Matthew C. Kapusta 在 3 月 4 日的交易中出售了 28,341 股公司的股票。該股票以平均價格 10.29 美元出售，總交易額為 291,628.89 美元。出售後，首席執行官現在直接持有 651,454 股公司的股票，價值為 6,703,461.66 美元。這代表其持股減少了 4.17%。該交易在向證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席財務官 Christian Klemt 在 2 月 27 日的交易中出售了 2,916 股公司的股票。該股票以平均價格 11.32 美元出售，總交易額為 33,009.12 美元。交易完成後，首席財務官現在直接持有 155,168 股公司的股票，價值約為 1,756,501.76 美元。此交易代表其持股減少了 1.84%。該交易的披露信息可在此找到。在過去三個月中，內部人士共出售了 90,830 股公司股票，價值為 961,401 美元。當前 4.74% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On uniQure</h2>
<div class="lb-trans"><h2>對 uniQure 的對沖基金觀點</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC purchased a new position in uniQure during the fourth quarter worth $38,410,000. Franklin Resources Inc. grew its holdings in uniQure by 33.1% during the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after purchasing an additional 494,726 shares during the last quarter. Point72 Asset Management L.P. raised its position in uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock worth $31,282,000 after purchasing an additional 794,459 shares during the period. Integral Health Asset Management LLC lifted its stake in uniQure by 175.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock worth $19,426,000 after purchasing an additional 700,000 shares during the last quarter. Finally, RTW Investments LP boosted its position in shares of uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after buying an additional 893,625 shares during the period. Institutional investors own 78.83% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該公司的股票。Avoro Capital Advisors LLC 在第四季度購買了 uniQure 的新頭寸，價值為 38,410,000 美元。Franklin Resources Inc.在第四季度將其在 uniQure 的持股增加了 33.1%。Franklin Resources Inc.現在持有 1,987,688 股生物技術公司的股票，價值為 35,103,000 美元，此前在上個季度又購買了 494,726 股。Point72 Asset Management L.P.在第四季度將其在 uniQure 的持股增加了 81.3%。Point72 Asset Management L.P.現在持有 1,771,352 股生物技術公司的股票，價值為 31,282,000 美元，此前在該期間又購買了 794,459 股。Integral Health Asset Management LLC 在第四季度將其在 uniQure 的持股增加了 175.0%。Integral Health Asset Management LLC 現在持有 1,100,000 股生物技術公司的股票，價值為 19,426,000 美元，此前在上個季度又購買了 700,000 股。最後，RTW Investments LP 在第四季度將其在 uniQure 的持股增加了 8,936.3%。RTW Investments LP 現在持有 903,625 股生物技術公司的股票，價值為 15,958,000 美元，此前在該期間又購買了 893,625 股。機構投資者持有該公司 78.83% 的股票。</p>
</div><h2>uniQure Company Profile</h2>
<div class="lb-trans"><h2>uniQure 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.</p>
<div class="lb-trans"><p>uniQure N.V.為患有罕見和其他嚴重疾病的患者開發治療方案。它提供的 HEMGENIX 已完成針對 B 型血友病的 III 期 HOPE-B 關鍵試驗。該公司還開發了 AMT-130，這是一種正在進行 I/II 期臨牀研究的基因治療，用於治療亨廷頓舞蹈症。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦閲讀</h2>
</div><ul>
<li>Five stocks we like better than uniQure</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>Top 3 Beverage Stocks Pouring Out Profits</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>CarMax and Carvana: Steering the Used Car Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 uniQure</li>
<li>如何投資 FAANG 股票</li>
<li>便士股票激增，SurgePays 上漲 70%：買入的一個理由，賣出的五個理由</li>
<li>什麼是歐元 STOXX 50 指數？</li>
<li>三大飲料股票帶來豐厚利潤</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>CarMax 和 Carvana：引領二手車市場</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in uniQure Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 uniQure 嗎？</h2>
</div><p>Before you consider uniQure, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 uniQure 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 uniQure 並不在名單上。</p>
</div><p>While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 uniQure 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

uniQure (NASDAQ:QURE) 股價下跌 4.2% - 原因如下